CD274 and non-small cell lung carcinoma: Prior to comparing ICIs in the PD-L1-positive (≥1%) group, we performed a network meta-analysis of predefined efficacy and safety outcomes by including the overall participants of six studies, REVEL, CheckMate057, CheckMate017, OAK, LUME-lung 1 and KEYNOTE-010, and based on its results, conducted a subgroup analysis of refractory or relapse PD-L1-positive (≥1%) advanced NSCLC.